SETD4 and neoplasm: The proportion of SETD4-positive qLCSCs in tumor tissues from advanced-stage (stages III and IV) patients (0.68 ± 0.13% and 0.78 ± 0.14%, respectively) was significantly higher than that in tumor tissues from early-stage (stages I and II) patients (0.12 ± 0.02% and 0.19 ± 0.04%, respectively) (Figure 2(c)).